Healthcare & TechNovo Nordisk Shuts Cell Therapy Unit, Licenses Parkinson's Drug to AI Platform as Stock Jumps 24.9%Salvado•Jul 23, 2026
European Pharma InnovationNovo Nordisk Stock Surges 24.9% as Danish Pharma Bets on AI-Native Drug Discovery ModelSalvado•Jun 27, 2026
European BiotechNovo Nordisk Exits Internal Cell Therapy, Licenses Parkinson's Program to AI PartnerSalvado•Jun 25, 2026
European PharmaNovo Nordisk Closes Cell Therapy Unit, Outsources Parkinson's to AI-Native PartnerSalvado•Jun 19, 2026
European PharmaNovo Nordisk Outsources Parkinson's Programs to AI Partner as Stock Surges 24.9%Salvado•Jun 9, 2026
European Pharmaceutical InnovationNovo Nordisk Licenses Parkinson's Therapy to AI Startup, Shares Rise 24.9% in 30 DaysSalvado•Jun 5, 2026
European PharmaNovo Nordisk's 24.9% Rally Backs AI Partnership Model Over In-House BiologySalvado•May 31, 2026
European PharmaNovo Nordisk Stock Surges 24.9% in 30 Days as AI Reshapes European Drug DiscoverySalvado•May 27, 2026
European Pharmaceutical InnovationNovo Nordisk Closes Cell Therapy Unit, Outsources Parkinson's to AI Partner as Stock Surges 25%Salvado•May 18, 2026
European PharmaNovo Nordisk Licenses Parkinson's Cell Therapy to AI Partner, Closes Internal UnitSalvado•May 16, 2026
European PharmaNovo Nordisk Stock Jumps 24.9% After Closing Cell Therapy Unit and Licensing Parkinson's Program to AI PartnerSalvado•May 13, 2026
